- Home
- PHIO vs COCP Comparison
PHIO vs COCP Comparison
Compare PHIO & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHIO | COCP |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 13.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHIO | COCP |
|---|---|---|
| Price | $1.07 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $10.67 | $6.00 |
| AVG Volume (30 Days) | ★ 378.0K | 70.5K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.90 |
| 52 Week High | $9.79 | $2.67 |
Technical Indicators
Market Signals| Indicator | PHIO | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 48.05 |
| Support Level | $1.00 | $0.91 |
| Resistance Level | $1.18 | $1.01 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 38.89 | 50.24 |
Price Performance
Historical ComparisonAbout PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).